One question is on Radicava. Vinita, which year can you launch it? Is it next one, two years or beyond that?
The Somerset where you have the PAI on Radicava?
Questions across 8 calls
Anubhav Agarwal
UBS
Lupin Limited
Cipla Limited
First question is on Lanreotide. Just trying to understand, let's say the index are production or supply to 100 before the problem started. Once you come back and let's say in April, would you be back to 100? That's Part A. Part B is, I think all the problems with the partner was driven by capacity expansion for Lanreotide. So, at what point of time would you let's say 100 will become 120 or 150 for you guys?
So, let's say in second half next year or let's say in FY'27, would you be like 50% higher than this 100, closer to 150, just as an idea, right?
Good evening. Just continuing on the question, Lanreotide, I am just trying to reconfirm that at your partner, there is no external constraint because of which the supply has been impacted because for European partner, supply was impacted in the June quarter. Now you face constraint in September and you're guiding for the December quarter also being impacted. So first, sounds strange that partner is expanding that's why 9 months of total capacity being out and severe shortage in Europe and you also facing shortage. So confirming that there is no external dependency for the partner, it is just because they were expanding that's why they're facing so much shortage.
And Umang, how do you get confidence that this will come back to full normal level?
Dr. Reddy's Laboratories Limited
Two questions. One is for MVN sir. Just trying to understand the selling expenses in this quarter. So, do they include any selling expense for NRT or they don't?
So, just trying to understand the SG&A sequentially, December over the September quarter . Selling expenses excluding amortization is up like Rs. 50 - 60 crores, whereas NRT itself should have selling expenses of Rs. 150+ crores. So what else has gone down that net increase is only Rs. 50 - 60 crores for us?
Divi's Laboratories Limited
One question I just want to understand. On the generic side, you made a comment that on the price reversion. Trying to understand what's causing this price reversion because my sense is that most of the molecules you are supplying, have been manufacturing for a very long time, you have a very large market share. So is it high inventory at the customer level, basically I'm doubting that there will be new approvals which is causing the price reversion. Can you elaborate on the generic segment here?
Second clarity. I think Nilima mentioned about that advancing shipment by three to four weeks to take care of the logistic issue. Just trying to understand this more. Since when you would have done this this quarter, or the last two or three quarters you've been doing it? That's one question here. Second is, what does it mean -- the customer is holding a month inventory higher here?
Gland Pharma Limited
One I am just trying to understand your R&D. So annually your R&D is about INR200 crores. And I understand from past calls that when you report R&D, part of the R&D is spent by the partners also. So can you just help if you are spending INR200 crores a year, what would be the gross R&D spend of partner plus you put together roughly?
So my question was on R&D. So, Gland R&D annually is about INR200 crores. And my understanding was and you can correct it. For any ANDA that you submit on an average, part of the R&D is reported by you, part of the R&D is spent by your partner. So, on a gross ba sis, the R&D is higher. So, I'm just trying to understand, when annually your R&D is about INR200 crores, your partner and you put together, on an average what would be the gross number?
Sun Pharmaceutical Industries Limited
Just first question is on Leqselvi litigation itself. I am just trying to understand the scope of this litigation. So, based on my reading, the litigation is mainly on 335 patent, where the expiry of this patent is December ‘26, which is like 2 years from now. So, two subparts to this question. One is, is the scope of litigation only for 2 years or the scope of litigation is beyond the 2 years as well? That’s one part of my question. And the second part of the question is that in terms of worst-case outcome, what is the worst outcome here that does Sun have to pay a higher royalty here? Or you may not be able to launch the drug itself for 2 years?
And Dilip bhai, on the second part of the question, so is this more the worst case on the extent of royalty that we need to pay with 10%, 20%? Or is it like do not launch at all for 2 years?
First, a clarity on what Murali sir talked about. One, on the specialty side, when you said that sequentially, half has come from ex U.S. and half has come from U.S. Is that excluding licensing income, milestone income, so let's say, is that current on US$286 million going to US$325 million that has come half in the U.S., non-U.S. Or you're talking about US$286 million going to US$370 million?
Okay. So we had a US$40 million increase. So it's US$20 million, US$20 million, roughly. That's what you mean, right?